at Zacks.com (Thu, 10:51AM)
Celgene's (CELG +1.9%) apremilast treatment for psoriatic arthritis meets primary efficacy goals in a Phase 3 study, and the biotech will now seek FDA and EU regulatory approval for the drug in 2013. Apremilast also achieved its primary goal in a separate study of patients with Behcet's disease, a rare inflammatory condition. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Thu, 8:59AM)
at Zacks.com (Tue, 4:45PM)
at Zacks.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs